Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Investor Presentation (June 2022)
23 slides from Argenica Therapeutics's investor presentation, Jun 17, 2022
Slide 1: Updated Investor Presentation ASX Announcement
ASX ANNOUNCEMENT UDPATED INVESTOR PRESENTATION Perth, Australia; 17 JUNE 2022 – Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, provides an updated version of the investor present
Slide 2: Argenica Therapeutics June 2022
ARGENICA THERAPEUTICS JUNE 2022 1 www.argenica.com.au
Slide 3: ARGENICA THERAPEUTICS
This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You shoul
Slide 4: ARGENICA THERAPEUTICS
ARGENICA THERAPEUTICS GRANTED PATENTS Granted in the EU, Japan Commercialise “best in class” China, and the US novel neuroprotective Neuroprotective peptide therapeutics to reduce brain that could offer protection to cell death following stroke the brain following stroke and FREE OF ENCUMBRANCES and
Slide 5: ARGENICA THERAPEUTICS
Total Shares on issue 86,922,250 Other ARGENICA THERAPEUTICS Inventors and Research Shareholders Shares subject to escrow for 24 months 1 22,625,752 SHAREHOLDERS 6 Team Options on issue (escrow for 24 months) 1 & 2 8,300,000 4.0% 4.5% 2.8% 12.3% 76.4% Options on issue (not escrowed) 3 1,700,000 Cash
Slide 6: ARGENICA THERAPEUTICS
Cell death in the brain, or infarction, results from inadequate ISCHEMIC STROKE EXAMPLE blood supply to the affected area. ARGENICA THERAPEUTICS BRAIN TISSUE DAMAGE (INFARCT) Initial infarction sets off a cascade of cell death. While no drug can stop the initial infarct injury, ARG-007 has multiple
Slide 7: ARGENICA THERAPEUTICS
ONLY 15 MILLION PEOPLE 10 PERCENT WILL LOW RECOVERY HAVE A STROKE RECOVER ALMOST RATE DUE TO BRAIN EACH YEAR1 COMPLETELY 3 CELL DAMAGE ARGENICA THERAPEUTICS Reduction in blood flow leads One in four people will have Long term disability to 1.9 million brain cells a stroke in their lifetime2 Lasting
Slide 8: ARGENICA THERAPEUTICS
Rapidly increasing level of Long term cell damage impacts neural cell death and damage patient outcomes and recovery ARGENICA THERAPEUTICS IN-FIELD TREATMENT REHAB HOSPITAL TRIAGE PLAN Patient in ambulance and 1-4 weeks acute arrives at emergency Diagnose type of stroke Current therapeutic treatment
Slide 9: ARGENICA THERAPEUTICS
Reduction in Reduction in neural cell death patient recovery and damage time ARGENICA THERAPEUTICS IN-FIELD TREATMENT REHAB HOSPITAL TRIAGE PLAN Patient in ambulance and 1-4 weeks acute arrives at emergency Diagnose type of stroke Current therapeutic treatment hospitalisation1 followed by intensive
Slide 10: ARGENICA THERAPEUTICS
Percentage reduction of brain tissue death after stroke 24 Hours after stroke 28 Days after stroke 100% INDUCED INDUCED 90% STROKE STROKE Reduction in brain cell death 80% can make a significant ARGENICA THERAPEUTICS difference to patients’ 70% outcome. It could mean the difference of walking, talki
Slide 11: ARGENICA THERAPEUTICS
REDUCES BRAIN POTENTIAL TO SAFE WITH NO TISSUE DEATH ADMINISTER IN ADVERSE EFFECTS THE FIELD ARGENICA THERAPEUTICS ARG-007 showed a 67% Pre-clinical studies showed ARG-007 No adverse effects were observed in reduction in brain tissue death does not exacerbate bleeding in preliminary PK and toxicolog
Slide 12: ARGENICA THERAPEUTICS
ARGENICA THERAPEUTICS Completion of preliminary study activities, including clinical site management setup, preparation of ethics submission and healthy volunteer patient recruitment. ANIMAL STUDY ANIMAL STUDY IN-HUMAN STUDY Characterise the safety profile of Determines how is Preparation of ethics
Slide 13: ARGENICA THERAPEUTICS
1. IMPROVE THE OF HOW EFFECTS THE BODY ARGENICA THERAPEUTICS 2. EVALUATE THE WHEN ADMINISTERED 3. DETERMINE THE 12 4. IDENTIFY ANY POSSIBLE www.argenica.com.au
Slide 14: ARGENICA THERAPEUTICS
ARGENICA THERAPEUTICS 4 cohorts, with each cohort Single site study conducted at Estimated 6 months, with Double-blind, randomised receiving a different dose of the Linear Clinical Research preliminary findings expected study where participants either 8 participants in facility in Western Australia.
Slide 15: ARGENICA THERAPEUTICS
Data collected from the Phase 1 clinical trial will be critical to progress into Phase 2 trials, where will be administered to stroke patients. While stroke is the current corporate and commercial focus, ARGENICA THERAPEUTICS safety data from the Phase 1 clinical trial can potentially be used to mov
Slide 16: ARGENICA THERAPEUTICS
PRECLINICAL PRECLINICAL EFFICACY SAFETY PHASE 1 PHASE 2 PHASE 3 Damage to the brain from STROKE ARGENICA THERAPEUTICS interruption of its blood supply. Surgically Induced Stroke (SIS) SIS occurs during or after surgery. Hypoxic ischemic encephalopathy (HIE) occurs when HIE the brain doesn't receive
Slide 17: ARGENICA THERAPEUTICS
ARGENICA THERAPEUTICS Stroke during surgery (perioperative stroke) can occur in up to 10% of patients undergoing high risk cardiac or brain surgery1. Close to 95% of these strokes are ischemic in nature, and outcomes tend to be worse than in non-surgical stroke patients1. Given patients are under an
Slide 18: ARGENICA THERAPEUTICS
ARGENICA THERAPEUTICS Hypoxic ischemic encephalopathy (HIE) is a type of brain dysfunction that occurs when the brain doesn't receive enough oxygen or blood flow for a period of time. HIE may develop during pregnancy, labour and delivery, or in the postnatal period. HIE is the leading cause of morta
Slide 19: ARGENICA THERAPEUTICS
Significant protective effect in other brain injury models 4 Axonal injury grade (0-4) 3 ARGENICA THERAPEUTICS Traumatic brain injury (TBI) usually results from a violent blow or jolt to the head or body. Preclinical studies show that ARG-007 reduces 2 neuronal injury after TBI. Neuroprotective phar
Slide 20: ARGENICA THERAPEUTICS
Dr Liz Dallimore Geoff Pocock CEO & Managing Director Non-Executive Chairman • PhD in Neuroscience (UWA) and an MBA (AGSM) • 20 years’ experience in commercialisation of emerging • Over 20 years' experience in R&D, technology technologies and capital markets commercialisation and management consulti
Slide 21: ARGENICA THERAPEUTICS
Prof. Bruno Meloni Geoffrey Donnan CSO & Research Lead Member - CAC Head of Stroke Laboratory Research at UWA and the Perron Institute. Professor Professor of Neurology at The University of Melbourne and former Director Meloni has over 25 years experience as a research scientist, the last 20 in the
Slide 22: ARGENICA THERAPEUTICS
3# PRE-CLINICAL DATA Positive pre-clinical results provide encouraging dataset leading into in-human trials. ARGENICA THERAPEUTICS 1# CLEAR PATHWAY TO TRIALS 2# 4# 5# Clear clinical pathway and EXCEPTIONAL NEAR TERM robust capital position to UNMET CLINICAL NEED TEAM CATALYSIS execute Phase 1 clinic
Slide 23: For further information please contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO E: info@argenica.com.au 22 www.argenica.com.au
Argenica Therapeutics — Investor Presentation (June 2022) on 6ix